Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS AUGUST ISSUE PUBLISHED
  • AUGUST 2020 Issue has been successfully launched on 1 August 2020.

Abstract

PHARMACOKINETIC EVALUATION OF OPTIMIZED VALSARTAN TABLETS FORMULATED EMPLOYING ? CD, CROSPOVIDONE AND SLS IN COMPARISON TO A MARKET PRODUCT

Ch . Tarakaramarao and K. P. R. Chowdary*

ABSTRACT

Valsartan, a widely prescribed anti hypertensive drug belongs to class II under BCS classification and exhibit low and variable oral bioavailability due to its poor aqueous solubility. It needs enhancement in the dissolution rate in its formulation development. Optimized valsartan tablet formulation with NLT 85% dissolution in 10 min could be developed employing βCD , Crospovidone and SLS by 23 factorial design. In the present study pharmacokinetic evaluation was done on optimized valsartan tablet formulation developed in comparison to a market product of valsartan tablets with an objective to evaluate their in vivo performance. Pharmacokinetic evaluation of the Optimized valsartan (40 mg) tablets in comparison to commercial valsartan (40 mg ) tablets (Valent-40) was done in healthy rabbits weighing 1.5 – 2.5 kg (n=6) of either sex in a cross over study at a dose of 40 mg of valsartan per tablet. The biological half – life (t ½) was found to be 5.06 h and 4.66 h respectively following the administration of optimized valsartan tablets formulated (Vopt) and Market product. With both the two products tested valsartan was found to be absorbed rapidly and peak concentration is achieved in 1 h. The absorption rate constant (Ka) was found to be 2.275 h-1 and 1.409 h-1 respectively with Vopt and Market product. The relative bioavailability (BA) of valsartan from the Vopt formulation was found to be 105.7 % when compared to Market product (100%). The optimized valsartan tablets formulated employing βCD, Crosspovidone and SLS are comparable to the market product with regard to in vivo performance.

Keywords: .


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More